POLLUX试验中达雷妥尤单抗联合来那度胺地塞米松治疗复发难治多发性骨髓瘤的健康相关生活质量分析
POLLUX III期试验中,D-Rd方案对比Rd方案显著改善复发难治多发性骨髓瘤的无进展生存期。本研究采用EORTC QLQ-C30和EQ-5D-5L问卷评估患者报告结局,发现D-Rd组在多个时间点的整体健康状况、躯体功能和疼痛评分较基线变化显著优于Rd组,但变化幅度较小,提示对健康相关生活质量无临床意义的影响。
要点
- D-Rd组在EORTC QLQ-C30整体健康状况、躯体功能和疼痛评分上多个时间点显著优于Rd组。
- 评分变化幅度较小,提示对健康相关生活质量无临床意义的影响。
- 长期D-Rd治疗中基线健康相关生活质量得以维持,支持其用于复发难治多发性骨髓瘤。
核心结论
- POLLUX试验中,长期D-Rd治疗可维持复发难治多发性骨髓瘤患者的基线健康相关生活质量。
研究设计与样本
- III期POLLUX试验的患者报告结局分析,使用EORTC QLQ-C30和EQ-5D-5L问卷评估。
- 采用混合效应模型计算基线变化的最小二乘均值变化及95%置信区间。
主要发现
- D-Rd组和Rd组至第40周期(第156周)的患者报告结局评估依从率均较高且相似。
- D-Rd组在EORTC QLQ-C30整体健康状况、躯体功能和疼痛评分上多个时间点的基线平均变化显著大于Rd组。
- 评分变化幅度较小,提示对健康相关生活质量无临床意义的影响。
- 亚组结果与总体人群相似。
临床怎么用
- D-Rd方案在改善无进展生存期的同时可维持复发难治多发性骨髓瘤患者的基线健康相关生活质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the phase 3 POLLUX trial, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly improved progression-free survival in patients with relapsed/refractory multiple myeloma (RRMM) compared with lenalidomide and dexamethasone (Rd) alone. Here, we present patient-reported outcomes (PROs) from POLLUX, assessed using the validated European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item (EORTC QLQ-C30) and the EuroQol 5-dimensional descriptive system (EQ-5D-5L) questionnaires. Changes from baseline are presented as least-squares mean changes with 95% confidence intervals (CIs) derived from a mixed-effects model. PRO assessment compliance rates were high and similar in both D-Rd and Rd groups through cycle 40 (week 156). In this on-treatment analysis, mean changes from baseline were significantly greater in EORTC QLQ-C30 global health status, physical functioning, and pain scores in the D-Rd group versus the Rd group at multiple time points; however, magnitude of changes was low, suggesting no meaningful impact on health-related quality of life (HRQoL). Subgroup results were similar to those in the overall population. In the POLLUX study, baseline HRQoL was maintained with prolonged D-Rd treatment. These findings complement the sustained and significant improvement in progression-free survival observed with D-Rd and supports its use in patients with RRMM. Clinical trial registration: NCT02076009.
引用
- Plesner T, Dimopoulos MA, Oriol A, et al. Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial. Br J Haematol. 2021. PMID: 33822368. doi:10.1111/bjh.17435
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。